StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes
March 10, 2026 2:28 PM
Truist Securities analyst Asthika Goonewardene reiterated a Buy rating and $155.00 price target on BioNTech (NASDAQ: BNTX)The analyst commented, "BNTX’s ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
